Docket Number:14A-941103
Inventor:Wen-ChinYang, Lee-Tian Chang
IP Status:US 7763285 B2、US 8147880 B2、US 8536141、TW I370738、TW I412508、 EP 1955701、US 8575116 B1、EP 2384758 B1
Abstract:
We have found a fraction from B. pilosa that increases insulin production from βcells and decreases blood glucose levels on diabetic db/db mice. Furthermore, we have isolated a pure compound at 25 ug/kg BW with the same activity on diabetic db/db mice. Those data indicate that the fraction can be use as a botanical therapeuticals or alternative/supplementary medications of type 2 diabetes. And the pure compound from B. pilosa can be served as medications or lead drugs to cure type 2 diabetes. The effective dose of pure compounds for sugar lowering is thousands times lower than that of 2-D-glucopyranosyloxy-1-hydroxy-5(E)-tridecene-7,9,11-triyne and 3-D-glucopyranosyloxy-1-hydroxy-6(E)-tetradecene- 8,10,12-triyne.
Fields of Application:
- A nutritional/food supplements for patients of type 2 diabetes.
- Botanical therapeuticals or alternative/supplementary medications for disorder of potassium and calcium channels.
- Pure compound from B. pilosa can be serves as a lead compound on quality control of medicine production.
- Pure compound from B. pilosa might be used after islet transplantation.
Advantages when compared to the existing technologies:
- The effective dose of pure compound for sugar lowering is thousands times lower than that of 2-D-glucopyranosyloxy-1-hydroxy-5(E)-tridecene-7,9,11-triyne and 3-D-glucopyranosyloxy-1-hydroxy-6(E)-tetradecene- 8,10,12-triyne..
- Potassium/ATP channel and calcium channel of cells can be used to confirm the enhancement of insulin secretion by pure compounds from B. pilosa..
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
